See more : Brinx Resources Ltd. (BNXR) Income Statement Analysis – Financial Results
Complete financial analysis of BioNxt Solutions Inc. (BNXT.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioNxt Solutions Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Asahipen Corporation (4623.T) Income Statement Analysis – Financial Results
- MEB Corporation Public Company Limited (MEB.BK) Income Statement Analysis – Financial Results
- Michang Oil Ind .Co.,Ltd. (003650.KS) Income Statement Analysis – Financial Results
- T-Flex Techvest PCB Co., Ltd. (3276.TWO) Income Statement Analysis – Financial Results
- Greaves Cotton Limited (GREAVESCOT.BO) Income Statement Analysis – Financial Results
BioNxt Solutions Inc. (BNXT.CN)
About BioNxt Solutions Inc.
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 372.25K | 297.44K | 286.50K | 345.65K | 208.12K | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 101.83K | 87.02K | 0.00 | 0.00 | 97.11K | 0.00 |
| Gross Profit | 372.25K | 195.62K | 199.48K | 345.65K | 208.12K | -97.11K | 0.00 |
| Gross Profit Ratio | 100.00% | 65.77% | 69.63% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 2.55M | 2.11M | 3.34M | 3.24M | 268.60K | 0.00 | 0.00 |
| General & Administrative | 2.77M | 3.25M | 6.85M | 6.37M | 5.19M | 770.86K | 53.82K |
| Selling & Marketing | 749.16K | 674.70K | 5.51M | 4.65M | 924.74K | 0.00 | -49.34K |
| SG&A | 3.52M | 3.93M | 12.36M | 11.01M | 6.11M | 770.86K | 4.49K |
| Other Expenses | 0.00 | 201.82K | 803.50K | 896.47K | 945.28K | 97.11K | 0.00 |
| Operating Expenses | 6.74M | 6.24M | 16.51M | 15.15M | 7.32M | 867.97K | 4.49K |
| Cost & Expenses | 6.78M | 6.34M | 16.60M | 15.15M | 7.32M | 867.97K | 4.49K |
| Interest Income | 0.00 | 1.14M | 731.87K | 297.08K | 105.06K | 0.00 | 0.00 |
| Interest Expense | 1.04M | 1.14M | 731.87K | 297.08K | 105.06K | 5.34K | 0.00 |
| Depreciation & Amortization | 195.76K | 215.60K | 823.22K | 896.47K | 945.28K | 97.11K | 53.82K |
| EBITDA | -6.48M | -11.51M | -19.19M | -16.05M | -6.66M | -758.15K | -4.48K |
| EBITDA Ratio | -1,742.02% | -1,950.20% | -5,381.92% | -4,023.45% | -2,965.12% | 0.00% | 0.00% |
| Operating Income | -6.37M | -6.04M | -16.31M | -14.97M | -7.16M | -855.26K | -4.48K |
| Operating Income Ratio | -1,710.51% | -2,032.30% | -5,692.90% | -4,331.55% | -3,442.43% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.36M | -6.83M | -4.32M | -2.28M | -549.39K | -5.77K | -5.00 |
| Income Before Tax | -7.72M | -12.87M | -20.75M | -17.25M | -7.71M | -860.60K | -4.49K |
| Income Before Tax Ratio | -2,074.68% | -4,326.89% | -7,241.88% | -4,989.74% | -3,706.40% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -493.91K | -110.74K | -357.49K | -45.02K | 5.34K | -53.82K |
| Net Income | -7.72M | -12.38M | -20.64M | -16.89M | -7.67M | -860.60K | -4.49K |
| Net Income Ratio | -2,074.68% | -4,160.84% | -7,203.23% | -4,886.32% | -3,684.77% | 0.00% | 0.00% |
| EPS | -0.08 | -0.15 | -0.29 | -0.30 | -0.15 | -0.02 | 0.00 |
| EPS Diluted | -0.08 | -0.15 | -0.29 | -0.30 | -0.15 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 96.54M | 83.77M | 70.23M | 57.22M | 50.18M | 48.66M | 45.99M |
| Weighted Avg Shares Out (Dil) | 99.32M | 83.77M | 70.23M | 57.22M | 50.18M | 48.66M | 45.99M |
Source: https://incomestatements.info
Category: Stock Reports